peoplePerson
Wendy Parulekar
Senior investigator behind CCTG's breast cancer trials, including the MA.17 and MA.32 studies of extended endocrine therapy and metformin.
Wendy Parulekar has led or co-led Canadian Cancer Trials Group breast cancer studies including MA.17R (extended letrozole) and MA.32 (metformin), and oversees the group's trial operations.
Role
Senior Investigator, Canadian Cancer Trials Group; Professor of Oncology, Queen's University
Institution
Specialisms
Breast cancerClinical trial conductEndocrine therapy
| Title | Journal | Year |
|---|---|---|
| Extending aromatase-inhibitor adjuvant therapy to 10 years (MA.17R) | NEJM | 2016 |